In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin

被引：54
作者：
Entenza, Jose M. [1 ]
Giddey, Marlyse [1 ]
Vouillamoz, Jacques [1 ]
Moreillon, Philippe [1 ]
机构：
[1] Univ Lausanne, Dept Fundamental Microbiol, CH-1015 Lausanne, Switzerland
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2010年 / 35卷 / 05期
关键词：
Daptomycin; Resistance; Staphylococcus aureus; Enterococcus faecalis; Enterococcus faecium; SIMULATED ENDOCARDIAL VEGETATIONS; METHICILLIN-RESISTANT; REDUCED SUSCEPTIBILITY; LIPOTEICHOIC ACID; BETA-LACTAM; BACTERICIDAL ACTIVITIES; PHARMACODYNAMIC MODEL; STANDARD THERAPY; VANCOMYCIN; GENTAMICIN;
D O I：
10.1016/j.ijantimicag.2009.12.022
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Daptomycin is bactericidal against meticillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate-resistant S. aureus (GISA) and vancomycin-susceptible and -resistant enterococci. However, selection for daptomycin-resistant derivatives has occasionally been reported during therapy in humans. Here we evaluate whether selection for daptomycin-resistant S. aureus or enterococci could be prevented in vitro by combining daptomycin with amoxicillin/clavulanic acid, ampicillin, gentamicin or rifampicin. Six strains of S. aureus (four MRSA and two GISA) and four strains of enterococci (two Enterococcus faecalis and two Enterococcus faecium) were serially exposed in broth to two-fold stepwise increasing concentrations of daptomycin alone or in combination with a fixed concentration [0.25x minimum inhibitory concentration (MIC)] of either of the second agents. The daptomycin MIC was examined after each cycle. Exposure to daptomycin alone gradually selected for S. aureus and enterococci with an increased MIC. Gentamicin did not prevent the emergence of daptomycin-resistant bacteria. Rifampicin was also unable to prevent daptomycin resistance, although resistance was slightly delayed. In contrast, amoxicillin/clavulanic acid or ampicillin prevented or greatly delayed the selection of daptomycin-resistant mutants in S. aureus and enterococci, respectively. Addition of amoxicillin/clavulanic acid or ampicillin to daptomycin prevents, or greatly delays, daptomycin resistance in vitro. Future studies in animal models are needed to predict the utility of these combinations in humans. (C) 2010 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码：451 / 456
页数：6
相关论文
共 55 条
[1]   Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459
[2]   CORRELATION OF PENICILLIN-INDUCED LYSIS OF ENTEROCOCCUS-FAECIUM WITH SATURATION OF ESSENTIAL PENICILLIN-BINDING PROTEINS AND RELEASE OF LIPOTEICHOIC ACID [J].
ALOBEID, S ;
GUTMANN, L ;
WILLIAMSON, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) :1901-1907
[3]   The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[4]   Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus [J].
Aubry-Damon, H ;
Soussy, CJ ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2590-2594
[5]   Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].
Benvenuto, Mark ;
Benziger, David P. ;
Yankelev, Sara ;
Vigliani, Gloria .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249
[6]   Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials [J].
Bliziotis, I. A. ;
Ntziora, F. ;
Lawrence, K. R. ;
Falagas, M. E. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (12) :849-856
[7]   Contribution of the Autolysin AtlA to the Bactericidal Activity of Amoxicillin against Enterococcus faecalis JH2-2 [J].
Bravetti, Anne-Lise ;
Mesnage, Stephane ;
Lefort, Agnes ;
Chau, Francoise ;
Eckert, Catherine ;
Garry, Louis ;
Arthur, Michel ;
Fantin, Bruno .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (04) :1667-1669
[8]   ROLES OF RIBOSOMAL-BINDING, MEMBRANE-POTENTIAL, AND ELECTRON-TRANSPORT IN BACTERIAL UPTAKE OF STREPTOMYCIN AND GENTAMICIN [J].
BRYAN, LE ;
KWAN, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (06) :835-845
[9]   Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy [J].
Burns, CA .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (02) :133-136
[10]   DAPTOMYCIN (LY146032) TREATMENT OF EXPERIMENTAL ENTEROCOCCAL ENDOCARDITIS [J].
BUSH, LM ;
BOSCIA, JA ;
KAYE, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (06) :877-881
123456